Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Validation of International Society of Urological Pathology (ISUP) grading for prostatic adenocarcinoma in thin core biopsies using TROG 03.04 ‘RADAR’ trial clinical data

Delahunt, B.1; Egevad, L.2; Srigley, J. R.3; Steigler, A.4; Murray, J. D.1; Atkinson, C.5; Matthews, J.6; Duchesne, G.7; Spry, N. A.8; Christie, D.9; Joseph, D.8; Attia, J.4,10; Denham, J. W.4

Pathology - Journal of the RCPA: October 2015 - Volume 47 - Issue 6 - p 520–525
doi: 10.1097/PAT.0000000000000318
ANATOMICAL PATHOLOGY
Buy

Summary: In 2014 a consensus conference convened by the International Society of Urological Pathology (ISUP) adopted amendments to the criteria for Gleason grading and scoring (GS) for prostatic adenocarcinoma. The meeting defined a modified grading system based on 5 grading categories (grade 1, GS 3+3; grade 2, GS 3+4; grade 3, GS 4+3; grade 4, GS 8; grade 5, GS 9–10). In this study we have evaluated the prognostic significance of ISUP grading in 496 patients enrolled in the TROG 03.04 RADAR Trial. There were 19 grade 1, 118 grade 2, 193 grade 3, 88 grade 4 and 79 grade 5 tumours in the series, with follow-up for a minimum of 6.5 years. On follow-up 76 patients experienced distant progression of disease, 171 prostate specific antigen (PSA) progression and 39 prostate cancer deaths. In contrast to the 2005 modified Gleason system (MGS), the hazards of the distant and PSA progression endpoints, relative to grade 2, were significantly greater for grades 3, 4 and 5 of the 2014 ISUP grading scheme. Comparison of predictive ability utilising Harrell's concordance index, showed 2014 ISUP grading to significantly out-perform 2005 MGS grading for each of the three clinical endpoints.

1Department of Pathology and Molecular Medicine, Wellington School of Medicine and Health Sciences, Wellington, New Zealand

2Department of Oncology – Pathology, Karolinska Institute, Stockholm, Sweden

3Department of Pathology and Molecular Medicine, McMaster University, Toronto, Canada

4School of Medicine and Public Health, University of Newcastle, Newcastle, NSW, Australia

5St Georges Cancer Care Centre, Christchurch

6Auckland Hospital, Auckland, New Zealand

7Peter MacCallum Cancer Centre, Melbourne, Vic

8Sir Charles Gairdner Hospital, Perth, WA

9Genesis Care, Tugun, Qld

10Hunter Medical Research Institute, Newcastle, NSW, Australia

Address for correspondence: Prof Brett Delahunt, Department of Pathology and Molecular Medicine, University of Otago, Wellington, PO Box 7343, Wellington South 6242, New Zealand. E-mail: bd@wnmeds.ac.nz

Received 27 July, 2015

Revised 29 July, 2015

Accepted 29 July, 2015

© 2015 Royal College of Pathologists of Australasia
You currently do not have access to this article

To access this article:

Note: If your society membership provides full-access, you may need to login on your society website